For example, GSK-J4, a selective inhibitor of JMJD3 and UTX, has been proved to exert anticancer activity in a variety of tumor cell types, with its unique advantages of low action concentration, almost non-toxicity to normal cells, and reversible modification (177–179). This evidence concerns the gene KDM6A and neoplasm.